FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington,	D.C.	20549	

washington,	D.C.	20548

OMB APPR	OVAL			
OMB Number:	3235-0287			
Estimated average bu	urden			
hours per response:	0.5			

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Schuchart Aaron						2. Issuer Name and Ticker or Trading Symbol LUMOS PHARMA, INC. [(LUMO)]							(Che	eck all app Direct Office	ationship of Reportin (all applicable) Director Officer (give title		10% Ov	wner	
(Last) 4200 MA SUITE 2	(Fir ARATHON 00	,	Middle)		08/1	3. Date of Earliest Transaction (Month/Day/Year) 08/11/2021							be Chief Business Offic						
(Street) AUSTIN (City)			8756 :ip)		4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Line) X Form filed by One Report Form filed by More than G								orting Pers	on				
		Table	I - Noi	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	Bene	ficia	lly Own	ed			
1. Title of Security (Instr. 3) 2. Transar Date (Month/Date)				Execution Date		Date,	3. 4. Securitie Disposed (Code (Instr. 8)		es Acqı Of (D) (uired (a Instr. 3	4 and Securi Benefi Owned		ities For icially (D) d Following (I) (n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) (D)	or F	rice		action(s) 3 and 4)			(Instr. 4)	
Common Stock 08/11/2				2021		P		300	A	1	\$7.35	1,3	1,337(1)(2)		D				
Common	Common Stock 08/12			08/12/	2021		P		1,700	P	1	\$7.42	2 3,0	3,037(1)		D			
		Tal									osed of, convertib				/ Owned	t			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	. Onversion Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)		of Deriv	r osed) r. 3, 4	6. Date Expirati (Month/	on Da			int of rities rlying ative rity (In:	(3. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amor or Num of Share	ber					

Explanation of Responses:

- 1. Includes 695 restricted stock units ("RSUs") previously reported as holdings of the Reporting Person granted under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in a series of four successive annual installments with the next installment occurring on February 1, 2022, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
- 2. Includes 109 shares acquired under the Lumos Pharma, Inc. 2010 Employee Stock Purchase Plan on June 30, 2021.

Remarks:

/s/ Ryan Trytten, attorney-in-

** Signature of Reporting Person

fact

08/13/2021

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.